Advisors & Friends

    • Michael Godwin
    • Managing Director, Resonant Venture Partners

    Michael Godwin has worked with venture backed startups in the software, consulting, wireless and online commerce industries since 1996. He has worked with many notable firms including: AT&T, Excite, Independent Online Distribution Alliance, Menlo Innovations, WebCrawler, and Zengine/MCSI.

    Michael currently serves on the board of directors of Accio Energy and Pinoccio. Additionally, he serves on the boards of the following Ann Arbor, MI based non-profit organizations: Ann Arbor Amateur Hockey Association and the Moo Duk Martial Arts Institute.

    Michael is a former managing director of the Wolverine Venture Fund’s student advisory board at the University of Michigan. During his time with the Wolverine Venture Fund, Michael conducted due diligence and invested in several companies across the information technology, manufacturing, life sciences and clean tech sectors. Michael spearheaded the effort to fully integrate the deal acquisition, collaboration, document tracking and knowledge transfer procedures into a single solution.

    Prior to his role with the Wolverine Venture Fund at the University of Michigan’s Ross School of Business, Michael was a consultant and software engineer with Menlo Innovations where he helped develop the software for the first production release of Accuri Cytometer’s C6 Flow Cytometer. In addition to his work with Accuri, he was also instrumental in helping Menlo secure some of its larger consulting agreements by applying his deep experience in early stage and corporate operations.

    Before working with Menlo Innovations, Michael designed and built the royalty allocation system for the Independent Online Distribution Alliance. IODA was named one of Fortune magazine’s 25 Breakout Companies for 2005 and a “Rising Star” in Deloitte’s Technology Fast 50 for Silicon Valley. IODA was acquired by Sony Music Entertainment (SME) for an undisclosed sum in June 2009.

    Prior to his role with IODA, Michael worked as a software engineer with WebCrawler, which was acquired by Excite. With Excite Prior, Michael was part of the $6.7B merger with AT&T/@Home – the largest M&A involving an internet firm at the time.

    Michael holds an MBA from the University of Michigan and a Bachelor of Music degree fromBerklee College of Music, Boston. During his time at the University of Michigan he won the VCIC Venture Capital Investment Challenge in 2008, the David T. Shelby Award for Outstanding Leadership through the Zell Lurie Institute for Entrepreneurial Studies in 2010 and was elected to and served on the Board of Community Values and Ethics from 2008-2010.

    Michael also has extensive experience in the music industry. Michael was a partner in a private San Francisco based publishing company and recording studio and has performed as a bassist, guitarist and singer with hundreds of independent and major label acts. He composed music for the feature film Way Past Cool, an independent feature film directed by academy award winner Adam Davidson. Michael was a prolific session player and performed on numerous releases by independent artists.

    Finally, Michael is an Ann Arbor native who returned to Ann Arbor from San Francisco with his wife Karen and son Oliver in 2005. Karen helped establish the Google office in Ann Arbor where she is a senior manager of a global division of the company. The Godwins lead a very active lifestyle that involves multiple sports and activities. Michael and Karen chose to raise Oliver in vibrant Ann Arbor because of the close proximity to family and cultural richness of the area.

    • Larry Freed
    • Founder, 2nd Stage Partners

    Larry is the CEO of 2nd Stage Partners, which supports early-stage and second-stage companies in building rapid, capital-efficient second-stage business maturity through a framework that blends consulting into step-in execution for maximum productivity, effectiveness, and increased revenue velocity.

    Prior to forming 2nd Stage Partners, Larry was the Founder and CEO of ForeSee, the world leader in customer experience analytics. He led the company from inception to successful exit in 2013, returning over 22 times the capital originally invested in the business while also growing revenue every quarter since the company was founded.

    Prior to founding ForeSee, Larry held several senior executive positions at Compuware Corporation and was CTO at Bank One.

    Larry has authored two books, Managing Forward and Innovating Analytics. Larry is currently on the University of Michigan Technology Transfer National Advisory Board, Wolverine Venture Fund Advisory Board and serves on the board of directors of technology companies IDV Solutions and Mindjet.

  • Harry Wilcox

    • Chief Operating Officer and General Partner
    • Flagship Ventures

    Harry joined Flagship Ventures in 2006, bringing a rich set of experiences and expertise in financial management, operations, fund management and strategy. His career spans 30 years and has involved many different roles and functions including Controller, CFO, Sr. VP BD, and CEO. He has also served on several Boards of Directors. In addition to his corporate experience, Harry was previously CFO of two venture capital firms, Highland Capital Partners where he was the founding CFO and General Partner, and prior to that, Charles River Ventures. Most recently he has served as CFO and then Sr. VP Corporate Development for EXACT Sciences (NASDAQ:EXAS), one of Flagship’s portfolio companies. In addition to EXACT Sciences, Harry led an active consulting practice which included roles as interim CEO of two biotech companies: Thrasos Therapeutics and Biostratum. Prior to this, Harry was Executive Vice President, Chief of Finance and Corporate Development of Pyrosequencing, a publicly-held European biotech company. Earlier, he had been the President and Chief Executive Officer of Cambridge NeuroScience, Inc. (NASDAQ:CNSI) until its sale to CeNeS Pharmaceuticals, and before that Sr. VP Business Development and CFO of Cellcor. As COO and General Partner at Flagship Ventures, Harry is responsible for the operational management of Flagship’s VentureLabsTM unit, serves as a member of Flagship’s investment committee, and oversees the firm’s financial operations and LP relations/fundraising. He was a board member of Accuri Cytometers prior to its successful sale to Becton Dickinson. He also plays a role as board member or advisor to select portfolio companies and is currently a board member of Black Duck, Celexion, Seahorse Bioscience, Seventh Sense Biosystems, Tangent Medical Technologies, Inc. and T2 Biosystems.

  • Jack K. Ahrens II

    • TGap Ventures

    Jack has been a venture capitalist and fund administrator since 1979; first as President of United Capital Corporation of Illinois (an SBIC), since 1983 as a General Partner of Pathfinder Venture Capital Funds I, II and III and since 2002 Founding General Partner of TGap Ventures. Prior to that he had seven years of experience in bank trust investments and operations. He became a Chartered Financial Analyst (CFA) in 1982 and has advanced training at the American Institute of Banking, NASBIC Management Institute, and Stanford Advance Management College. He is a graduate of Indiana University. Jack also seres as a Director for MedVantx, Inc., NeoChord, Inc., Rapid Diagnostek, Inc. and Regenesis Biomedical, Inc.

  • Marc Weiser

    • Managing Director
    • RPM Ventures

    Marc Weiser is Founder and Managing Director of RPM Ventures, a seed and early stage venture firm focused on information technology. For RPM, Marc is currently involved with the boards of Automatic, BountyJobs, Glyde, Kontextual, Mojo Motors, ShareThis and Xtime. He is also responsible for the firm’s investments in Giftly, Luvocracy, SoFi, and Wide Open Spaces. Previous investments include: Applimation (acquired by Informatica – NASDAQ:INFA), OpenLane (acquired by Kar Holdings – NYSE: KAR), R4 Global Services (acquired by Verisign – NASDAQ:VRSN), RiverGlass (acquired by Allen Systems), and TetraVitae (acquired by Eastman Chemical – NYSE:EMN). Prior to forming RPM, Mr. Weiser was an internet and software entrepreneur. He co-founded QuantumShift, a provider of web-based business-to-business technology and services focused on corporate telecommunications needs. He was also an early employee at MessageMedia (acquired by DoubleClick) where he pioneered some of the original methods for e-commerce and helped lead the company’s IPO. In addition to his board roles for RPM, Mr. Weiser serves on the boards of McKinley, Inc., the Center for Entrepreneurship (CFE) and Wolverine Venture Fund at the University of Michigan, where he is an adjunct professor. He is the recipient of the University of Michigan College of Engineering Alumni Distinguished Service Award for his efforts in founding the CFE, the TechArb (student accelerator), and the Masters in Entrepreneurship (a joint program between the College of Engineering and Ross School of Business). Additionally, he and his wife are leading the creation of the Food Allergy Center at the University of Michigan. This Center will provide national leadership and a path to a cure for those that suffer from food allergies. He graduated cum laude from the University of Michigan with a BSE in aerospace engineering and a MBA with highest honors.

  • Mary Lincoln Campbell

    • Managing Director
    • EDF Ventures

    Mary L. Campbell is a Managing Director and founder of EDF Ventures. She has been an active investor both in healthcare and technology companies for over twenty years. Currently, Mary sits on the boards of the following companies: Arxan Technologies, a company developing next generation anti-tamper solutions to enable software programs to nullify software tampering and piracy; IntelePeer, a VoIP based interconnection, gateway and enhanced telephony services for VoIP and PSTN private/local exchange carriers; and ValenTx, a medical device company treating morbid obesity. She is also a board observer for the following companies: Cerenis Therapeutics, a developer of drugs for the treatment of cardiovascular and metabolic diseases; and Lycera, a pharmaceutical company developing drugs to fight diseases of the immune system. Mary led several of the firm’s most successful transactions including: Pixelworks, a leader of system-on-a-chip integrated circuits for the advanced display market which became a public company; HandyLab, a developer of molecular diagnostic assays and automation platforms, sold to Becton Dickinson & Company; Sircon, a provider of automation solutions for the insurance industry, sold to Vertafore, the nation’s number one insurance software provider; and Greenplum, a database clustering software for business intelligence and data warehousing, sold to EMC Corporation, the world’s leading provider of information infrastructure solutions. Mary is active with The Stephen M. Ross School of Business at the University of Michigan and currently serves as an advisor to the Zell Lurie Institute for Entrepreneurial Studies as well as its student-run venture activity, the Wolverine Venture Fund. She is an advisor to the University of Michigan’s Life Science Institute and serves on the Advisory Board of The Charles F. Dolan School of Business at Fairfield University. Mary has also served as past president and board member of the Michigan Venture Capital Association, the State’s premier public policy advocate for the private equity/venture capital industry. Mary received her MBA and BA in English from the University of Michigan and a Master of Special Education from Fairfield University.

  • Mina Patel Sooch

    • Founder & General Partner
    • Apjohn Ventures Fund

    Mina Sooch is President and CEO of ProNAi. She has over 20 years of pharmaceutical and healthcare experience as a venture capitalist, entrepreneur, and advisor for operations, strategy and finance. She co-founded Apjohn Ventures, Apjohn Group, several local biotech start-ups including Afmedica and ProNAi, and served as entrepreneur-in-residence at Northcoast VC in Michigan. Ms. Sooch has served on over 10 private, public, and VC industry boards including biotech companies ProNAi and Zystor, and past chairman of the Board of the Michigan Venture Capital Association. She served as global account manager at Monitor Group, a top tier global strategy consulting firm based in Boston from 1993-2000. Her client base consisted of mid-cap and large-cap healthcare companies and multi-billion dollar private equity companies. With a focus on M&A and partnership deals, she worked on over 30 deals including $7B Pharmacia & Upjohn merger in 1995. Ms. Sooch received a MBA from Harvard Business School in 1993. She graduated summa cum laude and commencement speaker from Wayne State University in 1989 with a B.S. in Chemical Engineering.

  • Timothy B. Petersen

    • Managing Director
    • Arboretum Ventures

    Tim Petersen joined Arboretum Ventures as a Managing Director in 2002. His investments primarily target capital-efficient companies in health IT and services that redefine efficient models for care delivery and improving access to care. Tim has led investments and held board seats for Arboretum in more than a dozen portfolio companies, including HealthMedia, which was acquired by J&J in 2008, and Accuri Cytometers, which was acquired by BD in 2011 for $205 million. From 1999 to 2002, Tim worked for the Zell Lurie Institute for Entrepreneurial Studies at the University of Michigan, serving as its Managing Director. During his tenure at Michigan, he also directed the activities of the Wolverine Venture Fund, the Institute’s venture capital fund focusing on early-stage life science and technology investments. Tim is involved in a number of community efforts focused on venture capital and entrepreneurship and has served as chairman of the Michigan Venture Capital Association. He holds a BA in Economics from Williams College, an MS in Economics from the University of Wisconsin-Madison, and an MBA from the Ross School of Business at the University of Michigan.

  • Timothy M. Mayleben

    • President & CEO
    • Esperion Therapeutics

    Tim Mayleben is President and Chief Executive Officer of Esperion Therapeutics (NASDAQ: ESPR) and has been a member of the board of directors since February 2010. Prior to joining Esperion, Tim was President, CEO and a Director of Aastrom Biosciences, Inc. (NASDAQ: ASTM). Previously, Tim was President, Chief Operating Officer and a director of NightHawk Radiology Holdings, Inc. Prior to joining Nighthawk, Tim was the COO of the original Esperion, until its acquisition by Pfizer in 2004. Tim is an advisor to, investor in, and member of the board of directors of several life science companies, including DeNovo Sciences, kaleo, Lycera Corporation and Marinus Pharmaceuticals. Tim earned an M.B.A., with distinction, from the J.L. Kellogg Graduate School of Management at Northwestern University, and a B.B.A. from the University of Michigan, Ross School of Business.

  • Ryan Waddington

    • Partner
    • Arsenal Ventures

    Ryan Waddington joined Arsenal as a Partner in 2014 and heads their Michigan office. In 2010, he co-founded Huron River Ventures, a leading early-stage venture firm based in Ann Arbor, Michigan, that invests primarily in enterprise and consumer software companies serving the energy, transportation and agriculture sectors. Ryan has over 18 years of experience in investing, operating and consulting roles in energy, environmental and other sectors, and has led over $100 million worth of investments in more than 25 technology companies at seed, venture and growth equity stages, while at HRV, Ziff Brothers Investments, NextEnergy and DTE Energy. Ryan holds engineering degrees from the University of Michigan and the University of Wisconsin, and earned an MBA with Distinction from the Ross School of Business at University of Michigan, where participated in the Erb Institute for Global Sustainable Enterprise. Ryan lives in Dexter, Michigan with his wife, four children and yellow lab, Brady, and is passionate about fly fishing, hockey and University of Michigan football. Current and former Director/Observer roles: Sidecar, Ambiq Micro, Root3 Technologies, PeachWorks, Covaron Advanced Materials and Advent Solar (acquired by Applied Materials NASDAQ: AMAT) and Varsity News Network.

  • Steven Weinstein

    • Managing Director
    • Novartis Venture Fund

    Steve is a Managing Director in Novartis Venture Fund’s Cambridge, MA office. Steve focuses on both medical device and bio/pharma investments for the fund. He brings significant operating and venture capital experience to Novartis’ investing efforts. Steve joined the Fund in 2006 as a Managing Director. He has led the investments and serves/d on the board of the following companies: Ablation Frontiers (acquired by Medtronic), Autonomic Technologies Inc., Intersection Medical, Portaero, Sonitus Medical, and Visiogen (acquired by Abbott) Prior to Novartis, Steve was at Prism Venture Partners, where he focused on medical devices and served on the boards of iScience Interventional, and Sensitech (acquired by Carrier/UTX). Prior to Prism, Steve was a Kauffman Fellow with Mid-Atlantic Venture Funds. He started his career as an entrepreneur and CEO, raising angel funds to buy the assets of a defunct distribution business out of bankruptcy, and then rebuilt the business over the next five years. Steve holds an MBA with distinction from the University of Michigan Business School and a BS in mechanical engineering from Columbia University’s School of Engineering and Applied Science. He serves on the Innovation Advisory Board of the Cleveland Clinic, the Innovation Advisory Board of Partners Healthcare, and is a member of the Virginia GAP BioLife Fund Investment Committee.